Literature DB >> 18802030

Characterization of the steric defense of the HIV-1 gp41 N-trimer region.

Debra M Eckert1, Yu Shi, Sunghwan Kim, Brett D Welch, Eunchai Kang, Emily S Poff, Michael S Kay.   

Abstract

During viral entry, HIV gp41 adopts a transient conformation called the "prehairpin intermediate" in which a highly conserved therapeutic target, the N-trimer, is exposed. Despite extensive discovery efforts, potent and broadly neutralizing antibodies that target the N-trimer are elusive. We previously demonstrated the N-trimer is protected by a steric block that prevents large proteins, such as antibodies, from accessing it. Here we further characterize the steric block and identify its source. To study the N-trimer steric accessibility, we produced two sets of C-peptide inhibitors (a potent inhibitor targeting the N-trimer) fused to cargo proteins of increasing size facing either the virus or cell side of the prehairpin intermediate. Both bulky inhibitor sets show a steric block, but the effect is more pronounced with virus-side cargo. Additionally, both sets maintain their potencies in a modified entry assay that removes possible sources of target cell steric hindrance. These results implicate a viral source, likely gp120, as the primary component of the steric block. In addition, we studied the steric accessibility of the "pocket" region of the N-trimer, a highly attractive drug and vaccine target. We demonstrated a pocket-specific antibody, D5, is more potent as an scFv than as a full-length IgG, suggesting the N-trimer steric restriction extends to the pocket. This characterization will facilitate the design of sterically restricted antigens that mimic the steric environment of the N-trimer in the prehairpin intermediate and are capable of inducing potent and broadly neutralizing antibodies that circumvent the N-trimer steric block.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18802030      PMCID: PMC2590922          DOI: 10.1110/ps.038273.108

Source DB:  PubMed          Journal:  Protein Sci        ISSN: 0961-8368            Impact factor:   6.725


  41 in total

1.  Packaging system for rapid production of murine leukemia virus vectors with variable tropism.

Authors:  N R Landau; D R Littman
Journal:  J Virol       Date:  1992-08       Impact factor: 5.103

2.  Spectroscopic determination of tryptophan and tyrosine in proteins.

Authors:  H Edelhoch
Journal:  Biochemistry       Date:  1967-07       Impact factor: 3.162

3.  A synthetic peptide from HIV-1 gp41 is a potent inhibitor of virus-mediated cell-cell fusion.

Authors:  C Wild; T Greenwell; T Matthews
Journal:  AIDS Res Hum Retroviruses       Date:  1993-11       Impact factor: 2.205

4.  HIV-1 inhibition by a peptide.

Authors:  S Jiang; K Lin; N Strick; A R Neurath
Journal:  Nature       Date:  1993-09-09       Impact factor: 49.962

5.  Distinct modes of human immunodeficiency virus type 1 proviral latency revealed by superinfection of nonproductively infected cell lines with recombinant luciferase-encoding viruses.

Authors:  B K Chen; K Saksela; R Andino; D Baltimore
Journal:  J Virol       Date:  1994-02       Impact factor: 5.103

6.  Small-molecule inhibitors of HIV-1 entry block receptor-induced conformational changes in the viral envelope glycoproteins.

Authors:  Zhihai Si; Navid Madani; Jason M Cox; Jason J Chruma; Jeffrey C Klein; Arne Schön; Ngoc Phan; Liping Wang; Alyssa C Biorn; Simon Cocklin; Irwin Chaiken; Ernesto Freire; Amos B Smith; Joseph G Sodroski
Journal:  Proc Natl Acad Sci U S A       Date:  2004-03-29       Impact factor: 11.205

7.  Peptides corresponding to a predictive alpha-helical domain of human immunodeficiency virus type 1 gp41 are potent inhibitors of virus infection.

Authors:  C T Wild; D C Shugars; T K Greenwell; C B McDanal; T J Matthews
Journal:  Proc Natl Acad Sci U S A       Date:  1994-10-11       Impact factor: 11.205

8.  A synthetic peptide inhibitor of human immunodeficiency virus replication: correlation between solution structure and viral inhibition.

Authors:  C Wild; T Oas; C McDanal; D Bolognesi; T Matthews
Journal:  Proc Natl Acad Sci U S A       Date:  1992-11-01       Impact factor: 11.205

9.  N-linked glycosylation of the V3 loop and the immunologically silent face of gp120 protects human immunodeficiency virus type 1 SF162 from neutralization by anti-gp120 and anti-gp41 antibodies.

Authors:  Ruth A McCaffrey; Cheryl Saunders; Mike Hensel; Leonidas Stamatatos
Journal:  J Virol       Date:  2004-04       Impact factor: 5.103

10.  Vpr is required for efficient replication of human immunodeficiency virus type-1 in mononuclear phagocytes.

Authors:  R I Connor; B K Chen; S Choe; N R Landau
Journal:  Virology       Date:  1995-02-01       Impact factor: 3.616

View more
  21 in total

1.  Affinity maturation and characterization of a human monoclonal antibody against HIV-1 gp41.

Authors:  Donna L Montgomery; Ying-Jie Wang; Renee Hrin; Micah Luftig; Bin Su; Michael D Miller; Fubao Wang; Peter Haytko; Lingyi Huang; Salvatore Vitelli; Jon Condra; Xiaomei Liu; Richard Hampton; Andrea Carfi; Antonello Pessi; Elisabetta Bianchi; Joseph Joyce; Chris Lloyd; Romas Geleziunas; David Bramhill; Vicki M King; Adam C Finnefrock; William Strohl; Zhiqiang An
Journal:  MAbs       Date:  2009-09-08       Impact factor: 5.857

2.  Single-chain protein mimetics of the N-terminal heptad-repeat region of gp41 with potential as anti-HIV-1 drugs.

Authors:  Sara Crespillo; Ana Cámara-Artigas; Salvador Casares; Bertrand Morel; Eva S Cobos; Pedro L Mateo; Nicolas Mouz; Christophe E Martin; Marie G Roger; Raphaelle El Habib; Bin Su; Christiane Moog; Francisco Conejero-Lara
Journal:  Proc Natl Acad Sci U S A       Date:  2014-12-08       Impact factor: 11.205

3.  Site-Specific Polymer Attachment to HR2 Peptide Fusion Inhibitors against HIV-1 Decreases Binding Association Rates and Dissociation Rates Rather Than Binding Affinity.

Authors:  Maarten Danial; Angela N Stauffer; Frederik R Wurm; Michael J Root; Harm-Anton Klok
Journal:  Bioconjug Chem       Date:  2016-10-27       Impact factor: 4.774

4.  Pharmacokinetic and Chemical Synthesis Optimization of a Potent d-Peptide HIV Entry Inhibitor Suitable for Extended-Release Delivery.

Authors:  Joseph S Redman; J Nicholas Francis; Robert Marquardt; Damon Papac; Alan L Mueller; Debra M Eckert; Brett D Welch; Michael S Kay
Journal:  Mol Pharm       Date:  2018-02-22       Impact factor: 4.939

Review 5.  Monoclonal antibody-based candidate therapeutics against HIV type 1.

Authors:  Weizao Chen; Dimiter S Dimitrov
Journal:  AIDS Res Hum Retroviruses       Date:  2011-09-23       Impact factor: 2.205

Review 6.  Amphipathic properties of HIV-1 gp41 fusion inhibitors.

Authors:  Miriam Gochin; Guangyan Zhou
Journal:  Curr Top Med Chem       Date:  2011-12       Impact factor: 3.295

7.  Human Immunodeficiency Virus and Simian Immunodeficiency Virus Maintain High Levels of Infectivity in the Complete Absence of Mucin-Type O-Glycosylation.

Authors:  James M Termini; Elizabeth S Church; Zachary A Silver; Stuart M Haslam; Anne Dell; Ronald C Desrosiers
Journal:  J Virol       Date:  2017-09-12       Impact factor: 5.103

8.  Affinity maturation by targeted diversification of the CDR-H2 loop of a monoclonal Fab derived from a synthetic naïve human antibody library and directed against the internal trimeric coiled-coil of gp41 yields a set of Fabs with improved HIV-1 neutralization potency and breadth.

Authors:  Elena Gustchina; John M Louis; Christian Frisch; Francisco Ylera; Annette Lechner; Carole A Bewley; G Marius Clore
Journal:  Virology       Date:  2009-08-19       Impact factor: 3.616

Review 9.  Peptides in the treatment of AIDS.

Authors:  Fred Naider; Jacob Anglister
Journal:  Curr Opin Struct Biol       Date:  2009-07-23       Impact factor: 6.809

10.  Long-lasting enfuvirtide carrier pentasaccharide conjugates with potent anti-human immunodeficiency virus type 1 activity.

Authors:  Thierry Huet; Olivier Kerbarh; Dominique Schols; Pascal Clayette; Cécile Gauchet; Guy Dubreucq; Loïc Vincent; Heidi Bompais; Romain Mazinghien; Olivier Querolle; Arnaud Salvador; Jérôme Lemoine; Bruno Lucidi; Jan Balzarini; Maurice Petitou
Journal:  Antimicrob Agents Chemother       Date:  2009-10-05       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.